IFNB1 and myeloid sarcoma: The MS group was subdivided into two drug treatment groups: MS patients treated with fingolimod (MSW) and MS patients treated with other medications, such as beta-interferons, glatiramer acetate, and intravenous immunoglobulins (MSOs).